Ondine Biomedical Named Finalist for Best Communications Award at the 2025 European Mediscience Awards

Ondine Biomedical Inc. has been named a finalist for the Best Communications Award at the 2025 European Mediscience Awards, the premier annual event celebrating excellence in the life sciences sector across Europe. Ondine  is a pioneer in light activated anti microbials that kill all types of pathogens without causing resistance and a leader in highlighting the need for new technologies in the fight against AMR (Anti Microbial Resistance).

The Best Communications Award honours companies that have demonstrated outstanding clarity, consistency, and creativity in communicating their corporate story, vision, and value proposition to stakeholders, investors, and the broader healthcare community. Ondine’s nomination reflects its proactive efforts to engage with stakeholders around the urgent issue of antimicrobial resistance and the need for innovative, solutions in infection prevention to address the rise in  life-threatening healthcare acquired infections. In the US approximately two million patients suffer with healthcare-associated infections and nearly 90,000 are estimated to die. The overall direct cost of HAIs to hospitals ranges from US$28 billion to 45 billion.

“We are honoured to be recognized for our communications efforts,” Carolyn Cross, CEO of Ondine Biomedical, commented. “This nomination is a testament to our team’s commitment to raising awareness of hospital-acquired infections and promoting scientifically grounded, new solutions to one of healthcare’s most pressing challenges caused by anti microbial resistance. We are especially grateful to our staff, partners, and shareholders for supporting our mission to improve patient outcomes globally.”

A proud member of the CAN Health Network, Ondine represents the best of Canadian health innovation on the international stage as a global leader in medical devices that prevent and treat multidrug-resistant infections. The Company’s award-winning Steriwave® nasal photodisinfection technology which reduces  surgical site infections after major surgery by  more than 70% is being deployed in leading hospitals in Canada, the UK, and Switzerland. Steriwave is currently undergoing clinical trials to expand access into the intensive care and US markets.

The winners will be announced at a gala dinner on June 12, 2025, at the Hotel InterContinental, Park Lane, London.